New Drug Assay Technology Licensed
By HospiMedica staff writers
Posted on 06 Jun 2002
An exclusive license to a recently issued US patent for methods relating to the measurement of electrical waveforms of tissue or cells has been obtained by Tensor Biosciences (Irvine, CA, USA) from Matsushita Electric Industrial Co, Ltd. (Osaka, Japan). Tensor will apply the new technology to the development of in vitro drug screening assays.Posted on 06 Jun 2002
Tensor has combined computer science and multi-electrode neurophsyiology to develop more predictive technology for discovering neurotherapeutics. The company has various patents on methods for testing drugs on slices of living brain tissue. The technology described in the new patent relates to Tensor's advanced brain slice culture methods and their application to multisite electrophysiology. Applications could include drug candidate characterization, development of in vitro models of psychiatric and neurodegenerative disorders, and rapid on-site testing of chronic drug toxicities and side effects on networks of neurons, revealing lethal and nonlethal drug effects for up to three weeks.
"In close partnership with Matsushita and the University of California at Irvine, we have now pioneered a method for measuring long-term drug effects on living brain tissue,” said Dr. James Whitson, president and CEO of Tensor.
Related Links:
Tensor Biosciences
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
